Although Cardinal Health is not directly involved in McKesson's contract win with OptumRX, this development could increase competition in the healthcare supply chain sector, potentially putting pressure on Cardinal Health's market position and possibly affecting its stock price negatively in the short term.

While Evercore's role in reporting the contract win is positive, it does not directly impact its financials or stock price in the short term. However, it showcases Evercore's analytical and advisory capabilities, which could indirectly benefit its reputation in the long run.

Securing a contract with OptumRX is a major win for McKesson, indicating a potential increase in revenue and business operations. This development is likely to be viewed positively by investors, potentially leading to a short-term increase in McKesson's stock price.